Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

388 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
Buchmann I, Bunjes D, Kotzerke J, Martin H, Glatting G, Seitz U, Rattat D, Buck A, Döhner H, Reske SN. Buchmann I, et al. Among authors: kotzerke j. Cancer Biother Radiopharm. 2002 Apr;17(2):151-63. doi: 10.1089/108497802753773775. Cancer Biother Radiopharm. 2002. PMID: 12030109
A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.
Buchmann I, Kull T, Glatting G, Bunjes D, Hale G, Kotzerke J, Rattat D, Dohner H, Reske SN. Buchmann I, et al. Among authors: kotzerke j. Eur J Nucl Med Mol Imaging. 2003 May;30(5):667-73. doi: 10.1007/s00259-002-1106-9. Epub 2003 Feb 22. Eur J Nucl Med Mol Imaging. 2003. PMID: 12599012 Clinical Trial.
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Ringhoffer M, Blumstein N, Neumaier B, Glatting G, von Harsdorf S, Buchmann I, Wiesneth M, Kotzerke J, Zenz T, Buck AK, Schauwecker P, Stilgenbauer S, Döhner H, Reske SN, Bunjes D. Ringhoffer M, et al. Among authors: kotzerke j. Br J Haematol. 2005 Aug;130(4):604-13. doi: 10.1111/j.1365-2141.2005.05663.x. Br J Haematol. 2005. PMID: 16098076 Free article. Clinical Trial.
Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.
Zenz T, Schlenk RF, Glatting G, Neumaier B, Blumstein N, Buchmann I, von Harsdorf S, Ringhoffer M, Wiesneth M, Keller F, Kotzerke J, Röttinger E, Stilgenbauer S, Döhner H, Reske SN, Bunjes D. Zenz T, et al. Among authors: kotzerke j. J Nucl Med. 2006 Feb;47(2):278-86. J Nucl Med. 2006. PMID: 16455634 Free article. Clinical Trial.
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, Dohr D, Stefanic M, Buck A, Harsdorf SV, Glatting G, Grimminger W, Karakas T, Munzert G, Döhner H, Bergmann L, Reske SN. Bunjes D, et al. Among authors: kotzerke j. Blood. 2001 Aug 1;98(3):565-72. doi: 10.1182/blood.v98.3.565. Blood. 2001. PMID: 11468151 Free article. Clinical Trial.
388 results